<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="480">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327206</url>
  </required_header>
  <id_info>
    <org_study_id>62586</org_study_id>
    <nct_id>NCT04327206</nct_id>
  </id_info>
  <brief_title>BCG Vaccination to Protect Healthcare Workers Against COVID-19</brief_title>
  <acronym>BRACE</acronym>
  <official_title>BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, two-group, phase III randomised controlled trial in up to 4170 healthcare workers
      to determine if BCG vaccination reduces the incidence and severity of COVID-19 during the
      2020 pandemic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthcare workers are at the frontline of the coronavirus disease (COVID-19) pandemic.
      Participants will be healthcare workers in Australian hospital sites. They will be randomised
      to receive a single dose of BCG vaccine, or no BCG vaccine. Participants will be followed-up
      for 12 months with regular mobile phone text messages (up to weekly) and surveys to identify
      and detail COVID-19 infection. Additional information on severe disease will be obtained from
      hospital medical records and government databases. Blood samples will be collected prior to
      randomisation and at 12 months to determine exposure to severe acute respiratory syndrome
      coronavirus 2 (SARS-CoV-2). Where required, swab/blood samples will be taken at illness
      episodes to assess SARS-CoV-2 infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III, two group, multicentre, open label randomised controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 disease incidence</measure>
    <time_frame>Measured over the 6 months following randomisation</time_frame>
    <description>Number of participants with COVID-19 disease defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe COVID-19 disease incidence</measure>
    <time_frame>Measured over the 6 months following randomisation</time_frame>
    <description>Number of participants who were admitted to hospital or died (using self-reported questionnaire and/or medical/hospital records) in the context of a positive SARS-CoV-2 test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 incidence by 12 months</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of participants with COVID-19 disease defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe COVID-19 incidence by 12 months</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of participants with severe COVID-19 disease defined as hospitalisation or death in the context of a positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first symptom of COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Time to first symptom of COVID-19 in a participant who subsequently meets the case definition:
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of episodes of COVID-19 disease defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic SARS-CoV-2 infection</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of participants with asymptomatic SARS-CoV-2 infection defined as
Evidence of SARS-CoV-2 infection (by PCR or seroconversion)
Absence of respiratory illness (using self-reported questionnaire)
No evidence of exposure prior to randomisation (inclusion serology negative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work absenteeism due to COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days (using self-reported questionnaire) unable to work (excludes quarantine/workplace restrictions) due to COVID-19 disease defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bed confinement due to COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days confined to bed (using self-reported questionnaire) due to COVID-19 disease defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom duration of COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days with symptoms in any episode of illness that meets the case definition for COVID-19 disease:
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire), plus
positive SARS-Cov-2 test (PCR or serology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 pneumonia</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy with SARS-CoV-2</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical care admissions with SARS-CoV-2</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of admission to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical care admission duration with SARS-CoV-2</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation with SARS-CoV-2</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of participants needing mechanical ventilation (using self-reported questionnaire and/or medical/hospital records) and a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation duration with SARS-CoV-2</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days that participants needed mechanical ventilation (using self-reported questionnaire and/or medical/hospital records) and a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation duration with COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days of hospitalisation due to COVID-19 (using self-reported questionnaire and/or medical/hospital records).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality with SARS-CoV-2</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of deaths (from death registry) associated with a positive SARS-CoV-2 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Febrile respiratory illness</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of participants with febrile respiratory illness defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of febrile respiratory illness</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of episodes of febrile respiratory illness, defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work absenteeism due to febrile respiratory illness</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days (using self-reported questionnaire) unable to work (excludes quarantine/workplace restrictions) due to febrile respiratory illness defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bed confinement due to febrile respiratory illness</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days confined to bed (using self-reported questionnaire) due to febrile respiratory illness defined as
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom duration of febrile respiratory illness</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days with symptoms in any episode of illness that meets the case definition for febrile respiratory illness:
fever (using self-reported questionnaire), plus
at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/blocked nose (using self-reported questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Critical care admissions</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of admission to critical care (using self-reported questionnaire and/or medical/hospital records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of participants needing mechanical ventilation (using self-reported questionnaire and/or medical/hospital records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of deaths (from death registry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation duration with febrile respiratory illness</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days of hospitalisation due to febrile respiratory illness (using self-reported questionnaire and/or medical/hospital records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned work absenteeism</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Number of days of unplanned absenteeism for any reason (using self-reported questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation cost to treat COVID-19</measure>
    <time_frame>Measured over the 12 months following randomisation</time_frame>
    <description>Cost of hospitalisation due to COVID-19 reported in Australian dollars (using hospital administrative linked costing records held by individual hospitals and state government routine costing data collections to provide an estimate of the cost to hospitals for each episode of COVID-19 care)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic adverse events to BCG vaccination in healthcare workers</measure>
    <time_frame>Measured over the 3 months following randomisation</time_frame>
    <description>Type and severity of local and systemic adverse events will be collected in self-reported questionnaire and graded using toxicity grading scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4170</enrollment>
  <condition>Coronavirus Disease 2019 (COVID-19)</condition>
  <condition>Febrile Respiratory Illness</condition>
  <condition>Corona Virus Infection</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>BCG vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of BCG vaccine (BCG-Denmark). The adult dose of BCG vaccine is 0.1 mL injected intradermally over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the upper arm).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No BCG vaccine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will not receive the BCG vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG Vaccine</intervention_name>
    <description>Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection</description>
    <arm_group_label>BCG vaccine</arm_group_label>
    <other_name>Bacille Calmette-Guerin Vaccine</other_name>
    <other_name>Bacillus Calmette-Guerin Vaccine</other_name>
    <other_name>Statens Serum Institute BCG vaccine</other_name>
    <other_name>Mycobacterium bovis BCG (Bacille Calmette Gu√©rin), Danish Strain 1331</other_name>
    <other_name>BCG Denmark</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Employed by one of the hospitals involved in the study

          -  Provide a signed and dated informed consent form

          -  Pre-randomisation blood collected

        Exclusion Criteria:

          -  Has any BCG vaccine contraindication

          -  Fever or generalised skin infection (where feasible, randomisation can be delayed
             until cleared)

          -  Weakened resistance toward infections due to a disease in/of the immune system

          -  Receiving medical treatment that affects the immune response or other
             immunosuppressive therapy in the last year. These therapies include systemic
             corticosteroids (more than or equal to 20 mg for more than or equal to 2 weeks),
             non-biological immunosuppressant (also known as 'DMARDS'), biological agents (such as
             monoclonal antibodies against tumour necrosis factor (TNF)-alpha).

          -  Has a congenital cellular immunodeficiency, including specific deficiencies of the
             interferon-gamma pathway

          -  Has a malignancy involving bone marrow or lymphoid systems

          -  Has any serious underlying illness (such as malignancy). Please note: People with
             cardiovascular disease, hypertension, diabetes, and/or chronic respiratory disease are
             eligible if not immunocompromised

          -  Known or suspected HIV infection, even if asymptomatic or has normal immune function.
             This is because of the risk of disseminated BCG infection

          -  Has active skin disease such as eczema, dermatitis or psoriasis at or near the site of
             vaccination. A different site (other than left arm) can be chosen if necessary

          -  Pregnant or breastfeeding Although there is no evidence that BCG vaccination is
             harmful during pregnancy or breastfeeding, it is a contra-indication to BCG
             vaccination. Therefore, we will exclude women who think they could be pregnant.

          -  Another live vaccine administered in the month prior to randomisation

          -  Require another live vaccine to be administered within the month following BCG
             randomisation If the other live vaccine can be given on the same day, this exclusion
             criteria does not apply

          -  Known anaphylactic reaction to any of the ingredient present in the BCG vaccine

          -  BCG vaccine given within the last year

          -  Has previously had a SARS-CoV-2 positive test result

          -  Already part of this trial, recruited at a different hospital
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Nigel Curtis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Children's Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof Nigel Curtis, MBBS PhD</last_name>
    <phone>+613 93456366</phone>
    <email>nigel.curtis@rch.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaya Gardiner</last_name>
    <phone>+613 99366461</phone>
    <email>kaya.gardiner@mcri.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Epworth Victoria Parade</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Nicole Tan, MBBS FANZCA</last_name>
      <phone>+61 3 9427 7899</phone>
      <email>niki.tan@anaestheticservices.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Nigel Curtis, MBBS PhD</last_name>
      <phone>+61 3 9345 6366</phone>
      <email>nigel.curtis@mcri.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Kaya Gardiner</last_name>
      <phone>+613 9936 6042</phone>
      <email>kaya.gardiner@mcri.edu.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Epworth Richmond</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Nicole Tan, MBBS FANZCA</last_name>
      <phone>+61 3 9427 7899</phone>
      <email>niki.tan@anaestheticservices.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epworth Eastern</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Nicole Tan, MBBS FANZCA</last_name>
      <phone>+61 3 9427 7899</phone>
      <email>niki.tan@anaestheticservices.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health- Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A/Prof Tony Korman, MBBS FRACP</last_name>
      <phone>+61 3 9594 4533</phone>
      <email>tony.korman@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Laurens Manning, MBChB PhD</last_name>
      <phone>+61 8 6152 2222</phone>
      <email>laurens.manning@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof Peter Richmond, MBBS FRACP</last_name>
      <phone>+61 8 6456 5604</phone>
      <email>peter.richmond@uwa.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof Michaela Lucas, MD PhD</last_name>
      <phone>+61 8 6383 4311</phone>
      <email>michaela.lucas@health.wa.gov.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 6 months following analysis and article publications, for long-term use</ipd_time_frame>
    <ipd_access_criteria>Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

